; or (ii) disapprove the request if the drug subject to the request is not intended to treat or prevent such a disease; and (B) notify the requestor of such action and, for any disapproval, include in such notification an explanation of the reason for the disapproval. (3) Limitation A designation under paragraph (2) shall not be withdrawn for any reason, including modifications to the list of critical need antimicrobial priorities, unless the Secretary finds that the request for such designation contained an untrue statement of material fact. (l) Antimicrobial susceptibility testing devices As a condition on designation of a priority antimicrobial product pursuant to subsection (k), the sponsor of such product shall— (1) make such product available to antimicrobial susceptibility test device manufacturers as early in the development process as possible; and (2) submit a plan for such availability to the Secretary. (m) Appropriate use As a condition on designation of a priority antimicrobial product pursuant to subsection (k), the sponsor of such product shall agree to— (1) identify, track, and make publicly available antimicrobial resistance occurrence data and trends for such product; (2) develop, through the sponsor’s chief compliance officer, the sponsor’s chief medical officer, or another appropriate designee, written guidelines and procedures to ensure appropriate use of such product, including appropriate— (A) promotional practices; (B) education to encourage appropriate use; (C) surveillance and monitoring; and (D) stewardship; (3) develop education and communications strategies for educating health care professionals about such product and its appropriate use